Mesalazine Treatment in IBS (The MIBS Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

211 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Irritable bowel syndrome (IBS) is a condition characterised by abdominal pain or discomfort in combination with altered bowel function (stool frequency and/or stool consistency), currently defined by the Rome III criteria. The current IBS definition specifies that there are no structural or biochemical abnormalities to account for the symptoms but there is growing evidence that in at least a subset of IBS patients, a discrete immune activation might be a key pathogenetic factor. The condition is prone to develop after a gastroenteritis, post-infectious IBS, and increased numbers of lymphocytes, mast cells and pro-inflammatory cytokines like Interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α and a general increase in mucosal cellularity have been reported. Despite this, the efficacy of anti-inflammatory agents has been poorly investigated.

This will be a randomised, double blind, placebo-controlled, parallel-group, multi-centre study that aims to include a total of 200 subjects with irritable bowel syndrome (IBS). All subjects will be randomised to receive either 3x800 mg of mesalazine (Asacol®) or corresponding placebo once daily for a total treatment duration of 8 weeks. Males and females aged 18 to 70 years who already are diagnosed with IBS based on the Rome III diagnostic criteria and with a symptom intensity of at least moderate level; defined as an IBS Severity Scoring System (IBS-SSS) score of ≥175 at both Screening (Visit 1, Day -21±2) and Baseline (Visit 2, Day 0) will be eligible to enter the study.

Primary aim:

To assess the effect of mesalazine (Asacol®) treatment compared to placebo on global IBS symptoms: A treatment responder will be defined by answering the satisfactory relief of IBS-symptoms question "yes" at the end of at least 4 out of of 8 treatment weeks.

Secondary aims:

To assess mesalazine (Asacol®) treatment compared to placebo regarding:

1. Levels of inflammatory mediators in the rectal mucosa (e.g. neutrophil mediators, eosinophilic mediators, mast cell activity mediators and cytokines) measured by a new diagnostic tool, the Mucosal Patch Technology (MPT) by means of Enzyme-Linked Immunosorbent Assays (ELISA)
2. Effects on number of immune cells (count per high power field) and cytokine content (immunohistochemistry) in mucosal biopsies
3. Calprotectin levels in faeces (mg/kg)
4. Individual IBS symptom parameters derived from a symptom diary and also measured by IBS-SSS

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

NCT00934973

Irritable Bowel Syndrome

COMPLETED PHASE4

Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)

NCT01316718

Irritable Bowel Syndrome With Diarrhoea

COMPLETED PHASE4

Mesalazine Therapy in Patients With Irritable Bowel Syndrome

NCT00626288

Irritable Bowel Syndrome

COMPLETED PHASE3

A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome

NCT00774007

Irritable Bowel Syndrome

COMPLETED PHASE2/PHASE3

Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome

NCT02190526

Diarrhea- Predominant Irritable Bowel Syndrome Quality of Life

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mesalazine

Group Type EXPERIMENTAL

Mesalazine

Intervention Type DRUG

2400 mg q.d. for 8 weeks

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

3 tablets q.d. for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mesalazine

2400 mg q.d. for 8 weeks

Intervention Type DRUG

Placebo

3 tablets q.d. for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Asacol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females aged 18 to 70 years, both inclusive
* Subject is diagnosed with irritable bowel syndrome (IBS) prior to Screening based on the Rome III diagnostic criteria.
* Subject presents with IBS symptom intensity of at least moderate level; defined as an IBS Severity Scoring System (IBS-SSS) score of ≥175 at both Screening (Visit 1, Day -21±2) and Baseline (Visit 2, Day 0)
* Provision of signed informed consent

Exclusion Criteria

* Subjects who are unable to understand the written and verbal instructions
* Presence of a systemic inflammatory disease
* Presence of other gastrointestinal diseases likely to explain the IBS symptoms
* Presence of other severe somatic disease
* Treatment with non-steroidal anti-inflammatory drugs (NSAID), opioid analgetics or acetylsalicylic acid (ASA) compounds within 7 days prior to screening (Visit 1, Day -21±2)
* Treatment with systemic antibiotics within 28 days prior to Screening (Visit 1, Day -21±2)
* Treatment with immunosuppressant drugs within 28 days prior to Screening (Visit 1, Day -21±2)
* Other significant medical treatment, which, in the opinion of the investigator, may compromise the safety and efficacy objectives of the study, within 28 days prior to Screening (Visit 1, Day -21±2)
* Previously confirmed allergy towards ASA or mesalazine
* Presence of renal disease and/or concomitant treatment with medications with potential renal side effects
* Current ongoing infection
* History of, or current, drug or alcohol dependence
* Pregnant or lactating women
* Subjects suspected not to follow instructions based on the discretion of the Investigator
* Current participation in other intervention studies
* Female subjects of childbearing potential unwilling to use adequate contraceptive measures throughout the duration of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No